Recent Posts in ‘Biotech News’
ALR Technologies Updates Shareholders on Its FDA-Cleared Diabetes Management System
ALR Technologies Inc.(OTC.BB: ALRT.OB) (the “Company”), a healthcare technology company, is pleased to provide shareholders with an update on corporate developments since receiving 510(k) clearance from the U.S. Food and Drug Administration for its Health-e-Connect (HeC) System for remote monitoring of patients in support of effective diabetes management programs. As President Obama prepares to submit his 2013 budget
ImmunoCellular (IMUC) Accelerating ICT-107 Clinical Trial Enrollment for Glioblastoma
Immunocellular Therapeutics Ltd. (OTCBB: IMUC) is a biopharmaceutical company focused on improving cancer treatments through new immune-based products. Unlike other cancer treatment companies, such as Dendreon (NASDAQ: DNDN), Oncothyreon (NASDAQ: ONTY) , IMUC is developing immunotherapies that target cancer stem cells in addition to normal cancer cells as a means to delay and prevent cancer
Amarantus (AMBS) Licenses Parkinson’s Disease Biomarker Test from Power3
Amarantus BioSciences Inc. (OTCBB: AMBS) is a biopharmaceutical company that has discovered a revolutionary therapeutic protein that could change the way many major diseases are treated. Unlike Insmed Inc. (NASDAQ:INSM) or Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), MANF works by reversing the properties of cell apoptosis, which has shown strong signs of efficacy in a wide
Immunocellular Therapeutics (IMUC): Targeting Cancer Stem Cells
Immunocellular Therapeutics Ltd. (OTCBB: IMUC) is a biopharmaceutical company focused on improving cancer treatments through new immune-based products. Unlike similar companies, such as ImmunoGen Inc. (NASDAQ: IMGN) and Dendreon Corp. (NASDAQ: DNDN), IMUC is developing immunotherapies that target cancer stem cells in addition to normal cancer cells as a means to delay and prevent cancer
NFL Veterans Support Amarantus BioSciences’ Traumatic Brain Injury Research
Amarantus BioSciences Inc. (OTCBB: AMBS) is a biopharmaceutical company that has discovered a revolutionary therapeutic protein that could change the way many major diseases are treated. Unlike Insmed Inc. (NASDAQ:INSM) or Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), MANF works by reversing the properties of cell apoptosis, which has shown strong signs of efficacy in a wide